MLICM
PDSB icon

Metropolitan Life Insurance Company (MetLife)’s PDS Biotechnology PDSB Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio PDSB Stock Details PDSB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-235
Closed -$931 – 1528
2024
Q1 		$931 Sell
235
-1,312
-85% -$6.76K ﹤0.01% 2300
2023
Q4 		$7.69K Hold
1,547
– – ﹤0.01% 2250
2023
Q3 		$7.81K Hold
1,547
– – ﹤0.01% 2321
2023
Q2 		$7.78K Buy
+1,547
New +$10.1K ﹤0.01% 2407
2018
Q2 		– Sell
-355
Closed -$8.38K – 2484
2018
Q1 		$8.38K Buy
+355
New +$95.5K ﹤0.01% 2470

Other funds holding PDSB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
IWA
Inspirion Wealth Advisors Libertyville, Illinois $874M AUM 16.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s PDSB Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of PDS Biotechnology (PDSB) in Q2 2024, closing a stake of 235 shares — an estimated $931 sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in PDSB in Q1 2018 and held it in 5 quarters. The position peaked at $8.38K in Q1 2018. 77 funds tracked by Wall St. Rank hold PDSB as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining PDS Biotechnology position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 235 PDS Biotechnology shares in Q2 2024, an estimated $931.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in PDS Biotechnology in Q1 2018 and held it in 5 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s PDS Biotechnology position peaked at $8.38K in Q1 2018.
  • 77 funds tracked by Wall St. Rank held PDS Biotechnology as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.